Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michael Sims

Physician Assistant Longview, TX Physician Assistant

NPI 1427053180 CMS profile 10996290

805 Medical Dr, Longview, TX 75605

Open in the dashboard

General payments

$8,845

578 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Sims of Longview, TX is reported in the CMS Open Payments database as having received $8,845 across 578 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,453 93
2024 General $1,567 85
2023 General $2,184 139
2022 General $2,075 143
2021 General $1,565 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Sims
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Michael Sims were reported at $1,453. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Michael Sims Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,565 $132 $37–$438 $132
2022 $2,075 $155 $48–$522 $149
2023 $2,184 $167 $52–$557 $160
2024 $1,567 $178 $55–$600 $164
2025 $1,453 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,080 79 payments
  2. GlaxoSmithKline, LLC. $949 87 payments
  3. AbbVie, Inc. $890 69 payments
  4. Pfizer Inc. $791 26 payments
  5. Lilly USA, LLC $608 45 payments
  6. AstraZeneca Pharmaceuticals LP $586 33 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $468 31 payments
  8. Merck Sharp & Dohme Corporation $384 23 payments
  9. Amgen Inc. $324 24 payments
  10. Novartis Pharmaceuticals Corporation $315 29 payments
  11. Other $2,450 132 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,845 578 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $949 87 payments
  2. Ozempic $597 48 payments
  3. RYBELSUS $586 47 payments
  4. PREVNAR 20 $535 9 payments
  5. COMIRNATY $505 7 payments
  6. Wegovy $404 26 payments
  7. VRAYLAR $366 34 payments
  8. JARDIANCE $329 22 payments
  9. ABRYSVO $328 5 payments
  10. QULIPTA $328 18 payments
  11. Other $7,680 474 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 102 drugs

Part D claims

4,805

Median for Physician Assistant: 241

Drug cost

$370,713

Median for Physician Assistant: $4,110

Branded share of claims

16.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 41 $65,395
Mounjaro Tirzepatide Brand 38 $58,760
Farxiga Dapagliflozin Propanediol Brand 42 $47,590
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $27,628
Jardiance Empagliflozin Brand 31 $27,400
Januvia Sitagliptin Phosphate Brand 14 $20,804
Trulicity Dulaglutide Brand 19 $18,542
Repatha Sureclick Evolocumab Brand 21 $15,289
Xarelto Rivaroxaban Brand 14 $13,745
Eliquis Apixaban Brand 11 $13,211

The 10 drugs with the highest cost, of 102 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$137,778

Of which drugs: $35,845

Medicare patients

295

Average age 75

Services billed

7,619

121 women, 174 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 33%
Ischemic heart disease 33%
Chronic kidney disease 26%
Atrial fibrillation 21%
COPD 17%
Depression 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 21 21 $6,069
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 28 28 $2,291
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 24 55 $243

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $188
$188 24 —
Wegovy
  • Novo Nordisk Inc $81
$81 — —
NURTEC ODT
  • PFIZER INC. $80
$80 — —
VRAYLAR
  • AbbVie, Inc. $75
$75 — —
ABRYSVO
  • PFIZER INC. $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

578 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record